Additional results from RECOVER-AUTONOMIC clinical trials to be shared at upcoming conferences
Presenters will share findings on 2 possible treatments to manage symptoms of severe postural orthostatic tachycardia syndrome (POTS), a condition that some people develop with Long COVID.
Results from the RECOVER-AUTONOMIC clinical trials will be presented at 2 conferences in November, highlighting findings on whether Gamunex-C, a form of intravenous immunoglobulin (IVIG), and coordinated non-drug care can help manage symptoms of POTS following COVID-19.
Results about coordinated non-drug care from the RECOVER-AUTONOMIC Moderate POTS (Ivabradine) and RECOVER-AUTONOMIC Severe POTS (IVIG) clinical trials will be presented at the American Heart Association’s Scientific Sessions on November 9, 2026, in Chicago, Illinois. This abstract presentation, “Results from Primary Analysis of the Coordinated Versus Usual Nonpharmacologic Care for Postural Orthostatic Tachycardia Syndrome in Long COVID: A Pooled Analysis from the RECOVER-AUTONOMIC Platform Trial,” will start at 2:20 pm CT (3:20 pm ET) and is open only to those registered for the conference.
Results about both IVIG and coordinated non-drug care from the RECOVER-AUTONOMIC Severe POTS (IVIG) clinical trial will be presented at the American Autonomic Society’s 37th International Symposium on November 12, 2026, in San Diego, California. These presentations will start at 2:00 pm PT (5:00 pm ET) and are open only to those registered for the conference. After these sessions are presented, a public announcement about the results will be posted on recoverCOVID.org.
RECOVER-AUTONOMIC Severe POTS (IVIG) is one of 2 RECOVER clinical trials testing possible treatments in adults who have POTS as part of their Long COVID symptoms. An autonomic nervous system disorder, POTS is characterized by unexpectedly fast heart rate (without a significant drop in blood pressure) that occurs within 10 minutes of standing up from sitting or lying down. POTS symptoms can also include dizziness, fainting, fatigue, headaches, blurred vision, pain, weakness in the legs, or a combination of these symptoms, which can make it challenging to manage everyday responsibilities.
People participating in the trial were randomly assigned to receive either IVIG or saline placebo through intravenous (IV) infusion. IVIG is a repurposed drug that contains antibodies to help protect the body against infection from various diseases and is already approved by the U.S. Food and Drug Administration for the treatment of other health conditions. A placebo is given so that researchers have a group of study participants to compare to those who received the treatment. It is designed to look like the drug when it is given but does not have the drug’s effect. IV infusions are a common way for healthcare providers to give fluid, medicines, or nutrients to their patients.
Participants were also randomly assigned to receive either coordinated care or usual care (the healthcare they would normally receive) for 3 months. Coordinated non-drug care included regular check-ins with a care coordinator and specific recommendations for diet and lifestyle changes.
Read about the design of the RECOVER-AUTONOMIC clinical trials, published in the American Heart Journal.